NEW YORK (GenomeWeb News) — Alnylam Pharmaceuticals today said it has granted Bio-Rad non-exclusive rights to sell RNAi products based on certain of its IP.
 
The license falls under Alnylam’s Kreutzer-Limmer patent family, which covers the use of small interfering RNAs and “their use to mediate RNAi in mammalian cells,” the RNAi drug maker said.
 
Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.

Sep
12
Sponsored by
PerkinElmer

This webinar will cover recent advances in the use of CRISPR for generating animal models and cell lines.